| Bioactivity | DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research[1]. |
| Name | DOTA-JR11 |
| CAS | 1039726-31-2 |
| Sequence | DOTA-[p-Cl-Phe-cyclo(D-Cys-Phe-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2] |
| Formula | C74H98ClN19O21S2 |
| Molar Mass | 1689.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. |
DOTA-JR11
CAS: 1039726-31-2 F: C74H98ClN19O21S2 W: 1689.27
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.